Cogent Biosciences, Inc. SEC filings COGT
Cogent Biosciences, Inc. has 616 filings in SEC EDGAR's recent list, going back to Oct 20, 2014. Its latest annual report, Form ARS, was filed on Apr 23, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | May 9, 2025 | — |
| EFFECT | Filing | Apr 10, 2024 | — |
| CORRESP | Letter to the SEC | Apr 8, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 5, 2024 | — |
| EFFECT | Filing | May 24, 2022 | — |
| CORRESP | Letter to the SEC | May 20, 2022 | — |
| UPLOAD | Letter from the SEC | May 17, 2022 | — |
| EFFECT | Filing | May 13, 2022 | — |
| SEC STAFF LETTER | Filing | Mar 31, 2021 | — |
| EFFECT | Filing | Mar 18, 2021 | — |
| CORRESP | Letter to the SEC | Mar 16, 2021 | — |
| SEC STAFF LETTER | Filing | Mar 3, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 12, 2021 | — |
| EFFECT | Filing | Oct 15, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 13, 2020 | — |
| CORRESP | Letter to the SEC | Oct 6, 2020 | — |
| PRER14A | Filing | Oct 6, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 6, 2020 | — |
| CORRESP | Letter to the SEC | Oct 2, 2020 | — |
| PRER14A | Filing | Oct 2, 2020 | — |
| UPLOAD | Letter from the SEC | Sep 30, 2020 | — |
| CORRESP | Letter to the SEC | Sep 22, 2020 | — |
| PRER14A | Filing | Sep 22, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 25, 2020 | — |
| CORRESP | Letter to the SEC | Aug 19, 2020 | — |
| PRER14A | Filing | Aug 19, 2020 | — |
| UPLOAD | Letter from the SEC | Aug 12, 2020 | — |
| D | Filing | Jul 21, 2020 | — |
| D | Filing | Jul 21, 2020 | — |
| SC TO-I/A | Filing | May 11, 2020 | — |
| SC TO-I | Filing | Apr 8, 2020 | — |
| EFFECT | Filing | May 1, 2019 | — |
| CORRESP | Letter to the SEC | Apr 29, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 9, 2019 | — |
| CT ORDER | Filing | Mar 30, 2018 | — |
| CT ORDER | Filing | Mar 30, 2018 | — |
| EFFECT | Filing | Mar 28, 2018 | — |
| CERT | Filing | Mar 28, 2018 | — |
| 8-A12B | Filing | Mar 26, 2018 | — |
| CORRESP | Letter to the SEC | Mar 26, 2018 | — |
| CORRESP | Letter to the SEC | Mar 26, 2018 | — |
| CORRESP | Letter to the SEC | Mar 8, 2018 | — |
| DRSLTR | Filing | Feb 13, 2018 | — |
| DRS/A | Filing | Feb 13, 2018 | — |
| UPLOAD | Letter from the SEC | Dec 4, 2017 | — |
| DRS | Filing | Nov 3, 2017 | — |
| D | Filing | Jun 25, 2015 | — |
| D | Filing | Oct 20, 2014 | — |
Showing 49 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- COGT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1622229
- Former names
- Unum Therapeutics Inc. (until Oct 5, 2020); Unum Therapeutics, Inc. (until Mar 30, 2018)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.